首页>
外国专利>
Use of a combination of amoxicillin and clavulanate in the manufacture of a medicament for therapeutic drug resistant Streptococcus pneumoniae
Use of a combination of amoxicillin and clavulanate in the manufacture of a medicament for therapeutic drug resistant Streptococcus pneumoniae
展开▼
机译:阿莫西林和克拉维酸盐的组合在制备治疗性耐药性肺炎链球菌药物中的用途
展开▼
页面导航
摘要
著录项
相似文献
摘要
Infections potentially caused by DRSP may be treated by a method which comprises administering a pharmaceutical formulation comprising either: for an adult or older child patient from 800 to 1100 mg amoxycillin and from 100 to 150 mg clavulanate in a weight ratio between 6:1 and 10:1 inclusive; or for a paediatric patient from 30 to 40 mg/kg body weight of amoxycillin and from 3 to 8 mg/kg body weight of clavulanate in a weight ratio between 6:1 and 10:1 inclusive; in combination with a pharmaceutically acceptable carrier or excipient, three times a day(tid).
展开▼